Skip to content

Clinical study on the effect of PIFr optimization and EIT-guided DPI therapy on reducing the incidence of AECOPD

Clinical study on the effect of PIFr optimization and EIT-guided DPI therapy on reducing the incidence of AECOPD

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102642
Enrollment
Unknown
Registered
2025-05-16
Start date
2024-12-17
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease

Interventions

Experimental group:Inhaler training education including PIFr optimization and EIT (Pulmonary Electrical Impedance Imaging Machine)-based
Control group:Inhaler use education is given face-to-face based on physician experience

Sponsors

The Fourth Military Medical University, 986th Hospital of Air Force
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. Age >=40 years old; Smoking history >=20 pack-years; 2. The airflow is blocked after inhaling the branch expander (FEV 1/VC is less than 0.7); 3. Stable patients with symptoms consistent with COPD (dyspnea, cough, phlegm) who are being treated with DIP; 4. Expected survival >=12 weeks;

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1. Respiratory symptoms that include other causes, such as pulmonary embolism, congestive heart failure, worsening interstitial lung disease, pneumonia or pneumothorax; 2. Patients with serious basic diseases of important organs such as heart, lung, liver and kidney; 3. Cardiovascular and cerebrovascular events, such as acute cerebral infarction and acute coronary syndrome, occurred within 6 months before entering the study, and cardiovascular clinical symptoms or diseases were not well controlled; (1) New York Heart Association (NYHA) Grade 2 or higher heart failure; (2) LVEF (left ventricular ejection fraction) was < 50% by heart color ultrasonography; (3) Unstable angina; (4) supraventricular or ventricular arrhythmias that are clinically significant and require treatment or intervention. 4. Known history of psychotropic substance abuse or drug use; 5. There are other abnormalities that may increase the risk of participation or interfere with the study results, as well as patients deemed unsuitable for participation by the investigator.

Design outcomes

Primary

MeasureTime frame
Readmission rates for AECOPD;

Secondary

MeasureTime frame
COPD test score;Error rate of suction device use;Satisfaction with the suction device;All-cause mortality;Length of stay;FEV1/FVC abnormal area;

Countries

China

Contacts

Public ContactZhao Ke

The Fourth Military Medical University, 986th Hospital of Air Force

kezhao2001@126.com+86 180 6694 2427

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026